The SANT&#xC9; study at 10 years of follow-up: Effectiveness, safety, and sudden unexpected death in epilepsy

Aging and Cognitive FunctionsEpilepsy

Sudden Unexpected Death in Epilepsy Among Patients With Benign Childhood Epilepsy With Centrotemporal Spikes

JAMA Neurol.

Doumlele K, Friedman D, Buchhalter J, Donner EJ, Louik J, Devinsky O

doi: 10.1001/jamaneurol.

Epilepsy

Practice guideline summary: Sudden unexpected death in epilepsy incidence rates and risk factors

Neurology.

Harden C, Tomson T, Gloss D, Buchhalter J, Cross JH, Donner E, French JA, Gil-Nagel A, Hesdorffer DC, Smithson WH, Spitz MC, Walczak TS, Sander JW, Ryvlin P

doi: 10.1212/

Epilepsy

Investigative practice into sudden death in epilepsy: A global survey

doi: 10.1111/ane.13080.

Epilepsy

Final results from a Phase 3, long-term, open-label, repeat-dose safety study of diazepam nasal spray for seizure clusters in patients with epilepsy

Epilepsia

Wheless JW, Miller I, Hogan RE, Dlugos D, Biton V, Cascino GD, Sperling MR, Liow K, Vazquez B, Segal EB, Tarquinio D, Mauney W, Desai J, Rabinowicz AL, Carrazana E, DIAZ.001.05 Study Group.

doi: 10.1111/epi.17041

Epilepsy

Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307

Epilepsia.

Krauss GL, Perucca E, Kwan P, Ben-Menachem E, Wang XF, Shih JJ, Patten A, Yang H, Williams B, Laurenza A

doi: 10.1111/epi.14044.

Epilepsy

Long-term efficacy, tolerability, and retention of brivaracetam in epilepsy treatment: A longitudinal multicenter study with up to 5 years of follow-up

Epilepsia

Strzelczyk A, Zaveta C, von Podewils F, Möddel G, Langenbruch L, Kovac S, Mann C, Willems LM, Schulz J, Fiedler B, Kurlemann G, Schubert-Bast S, Rosenow F, Beuchat I

doi: 10.1111/epi.17087

Epilepsy

Potential years lost and life expectancy in adults with newly diagnosed epilepsy

Epilepsia.

Granbichler CA, Zimmermann G, Oberaigner W, Kuchukhidze G, Ndayisaba JP, Taylor A, Luef G, Bathke AC, Trinka E

doi: 10.1111/epi.13902.

Anxiety and Depression

A Longitudinal 5-Year Follow-Up Study of Cognitive Function After First Episode Major Depressive Disorder: Exploring State, Scar and Trait Effects

Front Psychiatry

Ronold EH, Schmid MT, Oedegaard KJ, Hammar Å

doi: 10.3389/fpsyt.2020.575867

Epilepsy

Evaluation of diazepam nasal spray in patients with epilepsy concomitantly using maintenance benzodiazepines: An interim subgroup analysis from a phase 3, long-term, open-label safety study

Epilepsia

Segal EB, Tarquinio D, Miller I, Wheless JW, Dlugos D, Biton V, Cascino GD, Desai J, Hogan RE, Liow K, Sperling MR, Vazquez B, Cook DF, Rabinowicz AL, Carrazana E, DIAZ.001.05 Study Group.

doi: 10.1111/epi.16901

Neurology · Psychiatry

The SANTÉ study at 10 years of follow-up: Effectiveness, safety, and sudden unexpected death in epilepsy

Related content

Sudden Unexpected Death in Epilepsy Among Patients With Benign Childhood Epilepsy With Centrotemporal Spikes

Practice guideline summary: Sudden unexpected death in epilepsy incidence rates and risk factors

Investigative practice into sudden death in epilepsy: A global survey

Final results from a Phase 3, long-term, open-label, repeat-dose safety study of diazepam nasal spray for seizure clusters in patients with epilepsy

Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307

Long-term efficacy, tolerability, and retention of brivaracetam in epilepsy treatment: A longitudinal multicenter study with up to 5 years of follow-up

Potential years lost and life expectancy in adults with newly diagnosed epilepsy

A Longitudinal 5-Year Follow-Up Study of Cognitive Function After First Episode Major Depressive Disorder: Exploring State, Scar and Trait Effects

Evaluation of diazepam nasal spray in patients with epilepsy concomitantly using maintenance benzodiazepines: An interim subgroup analysis from a phase 3, long-term, open-label safety study